Sentences with phrase «in tuberculosis vaccine»

Not exact matches

The study, «The efficacy of the BCG vaccine against newly emerging clinical strains of Mycobacterium tuberculosis,» was published in the journal PLOS One in September.

Orme and his research team in Fort Collins investigated whether the existing vaccine for TB, which goes by the acronym BCG (bacille Calmette - Guerin), worked equally well against different clinical strains of tuberculosis.

Recombinant vaccines rely on one or more antigens — proteins associated with the target bacterium — that boost an immune response; in this case Mycobacterium tuberculosis, which causes TB.

In collaboration with many researchers (graduate students, postdocs, and faculty elsewhere), we have examined the role of cross-immunity on the evolution and dynamics of influenza; the impact of behavioral changes, long periods of infectiousness, variable infectivity, co-infections, prostitution, social networks, and vaccine efficacy on HIV dynamics; the role of exogenous re-infection, variable progression rates, vaccination, public transportation, close and casual contacts on tuberculosis dynamics and control; the impact of life - history vector dynamics on dengue epidemics; and on the identification of time - response scales for epidemics of foot and mouth disease.

Today he directs the Innovations in International Health program at MIT, and his inventions (including an inhalable measles vaccine and a system that monitors tuberculosis treatment) are helping to improve medical access in the developing world.

Worse still, the results suggest it would be a mistake to use adenovirus - based vaccines against other diseases, such as malaria or tuberculosis, in areas where HIV is common.

He adds that the findings, which are published in the online 26 September issue of Nature Medicine, may be applicable to other infectious diseases such as tuberculosis, for which no highly effective vaccine exists.

Although the immune mechanisms implicated in the development of childhood asthma are not fully understood, some studies seem to suggest that the BCG vaccine, used in tuberculosis prevention, may have a protective effect on childhood asthma.

Frieden said the halt has raised concerns from researchers working on drug - resistant tuberculosis, the Ebola outbreak in Africa, and preparations for next season's influenza vaccine.

«You certainly can't do a $ 100 million study for every candidate vaccine that appears safe and immunogenic,» says Mark Mulligan, a molecular virologist who heads the vaccine center at Emory University in Atlanta and does human challenges with norovirus and tuberculosis.

The DarDar Trial remains the only trial in which a new tuberculosis vaccine has shown efficacy in humans.

An earlier form of the vaccine was used in the DarDar Trial, a seven - year study in Tanzania sponsored by the U.S. National Institutes of Health involving patients with HIV infection who at birth had received BCG, the current tuberculosis vaccine.

BCG, a vaccine against tuberculosis, was discovered in the 1920s and is one of the most used vaccines worldwide.

Studies in several countries have demonstrated that the tuberculosis vaccine BCG, when given early in life, confers some protection against acute leukaemia (Journal of the Royal Society of Medicine, vol 96, p 389).

«Taken together, these two studies suggest that the new scalable vaccine formulation is likely to prove as effective as the original formulation — which would make it the first protective TB vaccine in humans since BCG, which was introduced almost a century ago,» said Professor Ajit Lalvani, Director of the Tuberculosis Research Centre, National Heart and Lung Institute, Imperial College London and a member of the DAR - 901 development team.

Children who attend daycare in their first few months are much less likely to develop leukaemia than those who stay at home, for instance, while some tuberculosis vaccines reduce the risk of skin cancer.

The study, «The efficacy of the BCG vaccine against newly emerging clinical strains of Mycobacterium tuberculosis,» was published in September.

This has yielded three Tuberculosis vaccine candidates undergoing phase IIa testing and three first - in - human trials of novel CMI - inducing adjuvants.

New vaccines against malaria, tuberculosis and HIV are currently in field trials in the developing world.

We are also interested in the study of the roles of caspase - 2 in host responses induced by other vaccines (e.g., tuberculosis vaccine BCG).

Vaccine Design In this effort, many LJI scientists conduct pre-clinical studies relevant to design and optimize vaccines to combat infectious diseases like tuberculosis or dengue virus.

In addition, he is also a member of the Governing Board of the Tuberculosis Vaccine Initiative (TBVI) and past - chairman of the Human Vaccine Committee of the International Association for Biologicals (IABS) and of the WHO GACVS (Global Advisory Committee on Vaccine Safety).

The idea behind a â $ œHuman Vaccine Projectâ $ is to combine efforts at developing vaccines for major (but very different) diseases such as influenza, dengue, HIV, hepatitis C, tuberculosis and malaria, with the rationale that what scientists working on those diseases have in common is the Ray Ban outlet challenge of working with the human immune system.

He has also participated in technology transfer projects in Brazil and India, where a vaccine formulation center has been constructed to manufacture IDRI - developed adjuvant formulations for clinical trials to evaluate malaria, leishmania, and tuberculosis vaccines.

Similar to these projects, IDRI's subunit tuberculosis vaccine, ID93, also utilizes adjuvants that induce a cell - mediated immune response, which is required for protection against M. tuberculosis infection in low dose aerosol models of TB.

Before joining IDRI, Tracey worked as a Protocol Development Manager with the HIV Vaccine Trials Network at the Fred Hutchinson Cancer Research Center where she led multi-disciplinary teams in the design and implementation of clinical trials evaluating candidate HIV and tuberculosis vaccines.

She is completing her postdoctoral training at IDRI and is excited to use her background in adaptive immunity to help optimize vaccine strategies for pathogens like Mycobacterium tuberculosis.

She completed her doctorate work in Dr. Ian Orme's laboratory where she focused on the development of several novel vaccines against M. tuberculosis.

He currently serves as principal investigator on a $ 11.9 M contract from the National Institutes of Health (NIH) to develop a thermostable tuberculosis vaccine suitable for distribution in developing countries, involving formulation development, cGMP manufacturing, and clinical testing.

Among other things, it features articles on new developments in HIV cure research, recent studies that show promise but also possible pitfalls of using adenovirus vectors in HIV vaccine candidates, and the funding crisis at the Global Fund to Fight AIDS, Tuberculosis and Malaria.

In this effort, many LJI scientists conduct pre-clinical studies relevant to design and optimize vaccines to combat infectious diseases like tuberculosis or dengue virus.